Home > Publications database > From Basic Knowledge to Effective Therapies. > print

001     142473
005     20240229105148.0
024 7 _ |a 10.1016/j.ccell.2018.11.013
|2 doi
024 7 _ |a pmid:30537508
|2 pmid
024 7 _ |a 1535-6108
|2 ISSN
024 7 _ |a 1878-3686
|2 ISSN
024 7 _ |a altmetric:52670801
|2 altmetric
037 _ _ |a DKFZ-2019-00192
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Lipka, Daniel
|0 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
|b 0
|e First author
|u dkfz
245 _ _ |a From Basic Knowledge to Effective Therapies.
260 _ _ |a New York, NY
|c 2018
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1550145185_26422
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In this issue of Cancer Cell, Ott et al. use integrative analysis of histone ChIP-seq and ATAC-seq to describe enhancer-based regulatory circuits in chronic lymphocytic leukemia. This work identified and validated transcription factor PAX5 as main driver of an oncogenic circuitry, which can be disrupted by BET bromodomain inhibition.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Lutsik, Pavlo
|0 P:(DE-He78)ff1677c63392be9b31a1c8d23db7c9dc
|b 1
|u dkfz
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 2
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.ccell.2018.11.013
|g Vol. 34, no. 6, p. 871 - 873
|0 PERI:(DE-600)2074034-7
|n 6
|p 871 - 873
|t Cancer cell
|v 34
|y 2018
|x 1535-6108
909 C O |o oai:inrepo02.dkfz.de:142473
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c403a040c97f91902a7d31b93859f9fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)ff1677c63392be9b31a1c8d23db7c9dc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER CELL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b CANCER CELL : 2017
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21